The effects of ramucirumab and GSK1838705A were evaluated on two human HCC cell lines (PLC/PRF/5 and HepG2) characterized by different basal levels of AFP and DCP, in order to correlate the efficacy of specific drug treatments to the content of the two markers and possibly to detect changes in their expression following the treatments themselves. Here, ACE is linked to hepatocellular carcinoma.